News release: MDH approves labs for medical cannabis testing

News Release
April 29, 2015

Contact information

MDH approves labs for medical cannabis testing

The Minnesota Department of Health has approved two laboratories to test the composition and purity of cannabis medications produced by Minnesota’s two approved manufacturers. The laboratories that received approval are Aspen Research Corporation, Maple Grove, and Legend Technical Services, Inc., St. Paul.

“Minnesota’s medical cannabis program focuses providing patients with reliable, safe, medications,” said MDH Assistant Commissioner Manny Munson-Regala. “These labs will play a key role in ensuring these products meet Minnesota’s high medical standards.”

The approved laboratories will test products from Minnesota’s medical cannabis manufacturers, Minnesota Medical Solutions and Leafline Labs. The laboratories will test for THC and CBD levels and for potential contaminants, such as solvents, pesticides, microbiologicals and heavy metals. Testing will also include comparing the actual THC and CBD levels to the levels stated on product labels.

MDH chose the labs after a rigorous application process that included an inspection and verification of testing methods and operating procedures. Both labs were already state certified for other types of testing.

MDH and the state’s medical cannabis manufacturers are on track to start patient registration June 1 and distribution of medical cannabis July 1. Minnesota allows patients with qualifying conditions to use medical cannabis. Minnesota has a uniquely smoke-free program focused on providing patients safe and effective medications. Patients seeking medical cannabis need to complete these steps.

  • Have a health care practitioner certify your condition starting June 1.
  • Register at the MDH website.
  • Receive notification that MDH has approved you for the cannabis registry.
  • Visit a Cannabis Patient Center starting July 1.

Minnesota plans to have eight Cannabis Patient Centers across the state. Pharmacists at the centers will consult with patients about appropriate doses and forms, such as pills or liquids. Please visit the MDH medical cannabis website.


Media inquiries:

Scott Smith
MDH Communications